Blue Horseshoe Stocks: TPIV Recap, PZOO News & More

TapImmune, Inc. TPIV

Despite already being on one heck of a run, as we were stating in yesterday’s morning report, TPIV ended up having another landmark session in which it would surge to its highest PPS in almost a year.

The stock posted an early low of 1.20 before breaking out to 1.71, which registered as an intraday spike of 43% and occurred on heavy volume. TPIV also took the title of most actively-traded stock on the OTC for yesterday’s session, with shares changing hands 3,388 times.

We want to congratulate anyone who’s been tracking TPIV along with us recently; the total increase we’ve now observed in just eight sessions is equal to 137% (.72-1.71).

Yesterday’s continued uptrend was aided by the following PR:
TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients (Tue, Jun 23)


Pazoo, Inc. PZOO

Those of our subscribers that have joined our ranks in the past few weeks will need a little bringing up to speed on PZOO. We introduced this play at the beginning of April, and tracked it over an epic run from .0049 to .0204, which amounted to a 316% swing.

It has been nearly four weeks since we touched base with this play, and with a fresh PR released this morning, we think now would be a good time  to take another look. The stock has done well maintaining support throughout the month of June, trading in a channel between .009 to .011, holding a good bit of the advances we witnessed earlier in the Spring.

The storyline we’ve been following on PZOO of its 40% ownership in MA & associates, a Nevada-based marijuana testing agency, just got a whole lot more interesting with PZOO officially announcing that it has acquired the remaining 60% stake:

WHIPPANY, N.J., June 24, 2015 /PRNewswire/ — Pazoo, Inc. (OTC Pinks: PZOO) is pleased to report that on Wednesday, June 3, 2015,  Pazoo acquired the remaining 60% of MA & Associates, LLC in exchange for 900,000 shares of Pazoo’s Series C. Preferred stock. This now makes MA & Associates, LLC a 100% wholly-owned subsidiary of Pazoo. >>FULL PR


The MaryJane Group, Inc. MJMJ

MJMJ was among several stocks we tagged for potential upcoming bottom-plays at the end of last week, and while it did take the call an extra session to materialize, it did end up making that rebound yesterday.

The stock traded in a range from .0027-.0038; which marks an intraday swing of 41% on more than twice the average monthly volume. We’ll continue to monitor activity in the stock as the week progresses.


Under Armour, Inc. UA – Options

Yesterday morning, we updated readers as to the performance of the 07/31 $84 Calls that we initially alerted on Friday. From our observed low of 2.76, these contracts pushed further upward yesterday, extending to a new high of 4.20.

That pushes the overall range we’ve witnessed in just a two-session span to a respectable 52% We’ll continue to stay attuned to the activity as long as UA continues to perform well.


Extended Watchlist:
CPXX, NSPR, MEET, GBSN,

Blue Horseshoe Stocks: New Options Ideas, Bottom-Plays & More

Synergy Pharmaceutical, Inc. SGYP

SGYP kept piling on the gains yesterday with a great showing, emerging as one of our top picks of the week. For those who may have missed the reports, we declared interest in this play on Wednesday morning, and shortly thereafter bore witness to a solid 32% intraday run.

In yesterday morning’s report, we reinforced our confidence in the stock’s ability to produce another nice move based on the level of momentum it had built to that point. Our assumption proved accurate, and SGYP turned in an intraday increase of 19% from its early low of 7.92 up to a high of 9.44.

That move brought our total observed range on this play in a span of just two sessions to 56% (6.05-9.44).

SGYP is trading up slightly in the premarket with shares having traded hands for as much as 9.56 thus far this morning. While we’ll need to stay wary of potential pullbacks caused by profit-taking, we won’t want to let SGYP slip off of our radars.

The company’s Phase 3 trials for plecanatide as treatment for chronic idiopathic constipation met primary endpoints in both data runs, and there are many on Wall St. who believe we’ve yet to see the ceiling on this play’s potential.


`
Options Ideas

Under Armour, Inc. UA – We’re cap things off week by formulating a couple of options ideas for UA. The stock has been on quite a rip recently, and we’re going to explore the possibility of using the trend to our advantage. Specifically, we’re going to be monitoring UA Weekly $82.50-83.50 Calls for potential quick-strike intraday swing-trade chances, while reserving a spot on our longer-term watchlist for the 07/31 $84 Calls.

Added Reminder: We also are going to stay hot on the trail of the PBR Options ideas we mentioned in yesterday’s report (08/21 $10 and $11 Calls) into next week. We’ve already seen moves approaching and exceeding 100% in those contracts, and want to remain open to the possibility of more coming down the pipe, with plenty of time left until their expiration date.


Bottom-Bounce Watchlist:

Both Medican Enterprises, Inc. MDCN and Adaptive Media, Inc. ADTM took huge gut-punches yesterday, and will end the week on our bottom-watch radar. The possibility for significant rebound opportunities could be forthcoming either today or early into next week.


Extended Watchlist:
ARYC,  MJMJ, TPIV, HERO(Still on Bottom-Watch)